Danish Cancer Society

Blood Test Shows 96% Accuracy in Detecting Glioblastoma, Offering Hope for Earlier Diagnosis

- Researchers at the University of Manchester have developed a blood test using two protein markers that can detect glioblastoma with over 96% accuracy, potentially revolutionizing early diagnosis. - The test identifies coagulation factor IX (F9) and cartilage oligomeric matrix protein (COMP) in blood samples, providing a stable and robust signal despite tumor genetic diversity. - Clinical trials are now underway at six UK sites and four international locations, with hopes of developing a simple diagnostic device similar to a COVID test. - The breakthrough could reduce reliance on invasive surgical biopsies and MRI scans, enabling real-time monitoring of treatment response and disease progression.